{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T15:38:20Z","timestamp":1793029100583,"version":"4.5.0"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81903724"],"award-info":[{"award-number":["81903724"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004479","name":"Natural Science Foundation of Jiangxi Province","doi-asserted-by":"publisher","award":["20181BBG70008"],"award-info":[{"award-number":["20181BBG70008"]}],"id":[{"id":"10.13039\/501100004479","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004479","name":"Natural Science Foundation of Jiangxi Province","doi-asserted-by":"publisher","award":["20212BCJ23025"],"award-info":[{"award-number":["20212BCJ23025"]}],"id":[{"id":"10.13039\/501100004479","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Toxicology and Applied Pharmacology"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.taap.2023.116475","type":"journal-article","created":{"date-parts":[[2023,3,15]],"date-time":"2023-03-15T22:06:42Z","timestamp":1678918002000},"page":"116475","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Physiologically-based pharmacokinetic modeling-guided rational combination of tacrolimus and voriconazole in patients with different CYP3A5 and CYP2C19 alleles"],"prefix":"10.1016","volume":"466","author":[{"given":"Fei","family":"Gong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huihui","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Ouyang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng-Zheng","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Fang","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.taap.2023.116475_bb0005","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1124\/dmd.114.058834","article-title":"Expression of hepatic drug-metabolizing cytochrome P450 enzymes and their intercorrelations: a Meta-analysis","volume":"42","author":"Achour","year":"2014","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.taap.2023.116475_bb0010","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1080\/17425255.2017.1395413","article-title":"Pharmacokinetic considerations related to therapeutic drug monitoring of tacrolimus in kidney transplant patients","volume":"13","author":"Andrews","year":"2017","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.taap.2023.116475_bb0015","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1097\/01.ASN.0000073901.94759.36","article-title":"Association of the multidrug resistance-1 gene single-nucleotide polymorphisms with the tacrolimus dose requirements in renal transplant recipients","volume":"14","author":"Anglicheau","year":"2003","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.taap.2023.116475_bb0020","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1002\/cpt.113","article-title":"Clinical pharmacogenetics implementation consortium (CPIC) guidelines for CYP3A5 genotype and tacrolimus dosing","volume":"98","author":"Birdwell","year":"2015","journal-title":"Clin. Pharmacol. Ther."},{"issue":"12","key":"10.1016\/j.taap.2023.116475_bb0025","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1007\/s11095-020-02964-z","article-title":"Physiologically based pharmacokinetic models of probenecid and furosemide to predict transporter mediated drug-drug interactions","volume":"37","author":"Britz","year":"2020","journal-title":"Pharm. Res."},{"key":"10.1016\/j.taap.2023.116475_bb0030","doi-asserted-by":"crossref","first-page":"703","DOI":"10.2217\/pgs.10.43","article-title":"CYP3A5 and ABCB1 polymorphisms influence tacrolimus concentrations in peripheral blood mononuclear cells after renal transplantation","volume":"11","author":"Capron","year":"2010","journal-title":"Pharmacogenomics."},{"key":"10.1016\/j.taap.2023.116475_bb0035","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1136\/ejhpharm-2020-002385","article-title":"Effects of antifungal drugs on the plasma concentrations and dosage of tacrolimus in kidney transplant patients","volume":"29","author":"Cheng","year":"2020","journal-title":"Eur. J. Hosp. Pharm."},{"key":"10.1016\/j.taap.2023.116475_bb0040","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/j.1365-2125.2007.02874.x","article-title":"Influence of the CYP3A5 and MDR1 genetic polymorphisms on the pharmacokinetics of tacrolimus in healthy Korean subjects","volume":"64","author":"Choi","year":"2007","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.taap.2023.116475_bb0045","first-page":"105","article-title":"A pharmacogenomic study on the pharmacokinetics of tacrolimus in healthy subjects using the DMETTM plus platform","volume":"17","author":"Choi","year":"2017","journal-title":"Pharm. J."},{"key":"10.1016\/j.taap.2023.116475_bb0050","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/kisup.2011.14","article-title":"Pharmacogenetics of tacrolimus: ready for clinical translation?","volume":"1","author":"Coto","year":"2011","journal-title":"Kidney Int. Suppl."},{"key":"10.1016\/j.taap.2023.116475_bb0055","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1124\/dmd.105.008680","article-title":"Effect of CYP3A5 polymorphism on tacrolimus metabolic clearance in vitro","volume":"34","author":"Dai","year":"2006","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.taap.2023.116475_bb0060","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1023\/A:1018943613122","article-title":"Physiological parameters in laboratory animals and humans","volume":"10","author":"Davies","year":"1993","journal-title":"Pharm. Res."},{"key":"10.1016\/j.taap.2023.116475_bb0065","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.2165\/00003088-200645100-00005","article-title":"Development and evaluation of a generic physiologically based pharmacokinetic model for children","volume":"45","author":"Edginton","year":"2006","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.taap.2023.116475_bb0070","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1002\/psp4.12392","article-title":"A theoretical physiologically-based pharmacokinetic approach to ascertain covariates explaining the large interpatient variability in tacrolimus disposition","volume":"8","author":"Emoto","year":"2019","journal-title":"CPT Pharmacometrics Syst. Pharmacol."},{"key":"10.1016\/j.taap.2023.116475_bb0075","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1124\/dmd.111.039248","article-title":"Physiologically based pharmacokinetic modeling of intestinal first-pass metabolism of CYP3A substrates with high intestinal extraction","volume":"39","author":"Gertz","year":"2011","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.taap.2023.116475_bb0080","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.xphs.2018.10.033","article-title":"Physiologically based pharmacokinetic modeling in regulatory science: An update from the U.S. Food and Drug Administration\u2019s Office of Clinical Pharmacology","volume":"108","author":"Grimstein","year":"2019","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.taap.2023.116475_bb0085","doi-asserted-by":"crossref","DOI":"10.3390\/ph14030198","article-title":"Investigation of the impact of CYP3A5 polymorphism on drug-drug interaction between tacrolimus and Schisantherin a\/Schisandrin a based on physiologically-based pharmacokinetic modeling","volume":"14","author":"He","year":"2021","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.taap.2023.116475_bb0090","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S0009-9236(03)00168-1","article-title":"Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus","volume":"74","author":"Hesselink","year":"2003","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.taap.2023.116475_bb0095","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1007\/s40262-016-0416-1","article-title":"Dose-dependent bioavailability and CYP3A inhibition contribute to non-linear pharmacokinetics of Voriconazole","volume":"55","author":"Hohmann","year":"2016","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.taap.2023.116475_bb0100","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1002\/cpt.1529","article-title":"Prolonged-release tacrolimus is less susceptible to interaction with the strong CYP3A inhibitor Voriconazole in healthy volunteers","volume":"106","author":"Huppertz","year":"2019","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.taap.2023.116475_bb0105","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1002\/jcph.605","article-title":"Impact of cytochrome P450 2C19 polymorphisms on the pharmacokinetics of tacrolimus when coadministered with voriconazole","volume":"56","author":"Imamura","year":"2016","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.taap.2023.116475_bb0110","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1002\/psp4.12420","article-title":"A minimal physiologically-based pharmacokinetic model for tacrolimus in living-donor liver transplantation: perspectives related to liver regeneration and the cytochrome P450 3A5 (CYP3A5) genotype","volume":"8","author":"Itohara","year":"2019","journal-title":"CPT Pharmacometrics Syst. Pharmacol."},{"key":"10.1016\/j.taap.2023.116475_bb0115","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/S0090-9556(25)08219-4","article-title":"Isolation, identification, and biological activities of oxidative metabolites of FK506, a potent immunosuppressive macrolide lactone","volume":"21","author":"Iwasaki","year":"1993","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.taap.2023.116475_bb0120","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1128\/AAC.01123-08","article-title":"Comprehensive in vitro analysis of voriconazole inhibition of eight cytochrome P450 (CYP) enzymes: major effect on CYPs 2B6, 2C9, 2C19, and 3A","volume":"53","author":"Jeong","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.taap.2023.116475_bb0125","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1093\/ajhp\/52.14.1521","article-title":"Tacrolimus: a new immunosuppressive agent","volume":"52","author":"Kelly","year":"1995","journal-title":"Am. J. Health Syst. Pharm."},{"key":"10.1016\/j.taap.2023.116475_bb0130","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.ijpharm.2013.05.033","article-title":"From gut to kidney: transporting and metabolizing calcineurin-inhibitors in solid organ transplantation","volume":"452","author":"Knops","year":"2013","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.taap.2023.116475_bb0135","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1007\/s40262-019-00856-z","article-title":"A physiologically based pharmacokinetic model of Voriconazole integrating time-dependent inhibition of CYP3A4, genetic polymorphisms of CYP2C19 and predictions of drug-drug interactions","volume":"59","author":"Li","year":"2020","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.taap.2023.116475_bb0140","first-page":"14","article-title":"Physiologically based pharmacokinetic (PBPK) modeling of Clopidogrel and its four relevant metabolites for CYP2B6, CYP2C8, CYP2C19, and CYP3A4 drug-drug-gene interaction predictions","author":"Loer","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.taap.2023.116475_bb0145","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1067\/mcp.2001.113183","article-title":"The pharmacokinetics and metabolic disposition of tacrolimus: a comparison across ethnic groups","volume":"69","author":"Mancinelli","year":"2001","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.taap.2023.116475_bb0150","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1124\/dmd.111.043174","article-title":"Using expression data for quantification of active processes in physiologically based pharmacokinetic modeling","volume":"40","author":"Meyer","year":"2012","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.taap.2023.116475_bb0155","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1002\/jps.2600751104","article-title":"Man versus beast: pharmacokinetic scaling in mammals","volume":"75","author":"Mordenti","year":"1986","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.taap.2023.116475_bb0160","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1002\/cpt.1990","article-title":"Physiologically-based pharmacokinetic modeling characterizes the CYP3A-mediated drug-drug interaction between fluconazole and sildenafil in infants","volume":"109","author":"Salerno","year":"2021","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.taap.2023.116475_bb0165","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.tiv.2007.09.010","article-title":"General approach for the calculation of tissue to plasma partition coefficients","volume":"22","author":"Schmitt","year":"2008","journal-title":"Toxicol. in Vitro"},{"key":"10.1016\/j.taap.2023.116475_bb0170","first-page":"375","article-title":"Interindividual variability of CYP2C19-catalyzed drug metabolism due to differences in gene diplotypes and cytochrome P450 oxidoreductase content","volume":"16","author":"Shirasaka","year":"2016","journal-title":"Pharm. J."},{"key":"10.1016\/j.taap.2023.116475_bb0175","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1111\/ajt.13691","article-title":"A randomized controlled trial comparing the efficacy of Cyp3a5 genotype-based with body-weight-based tacrolimus dosing after living donor kidney transplantation","volume":"16","author":"Shuker","year":"2016","journal-title":"Am. J. Transplant."},{"key":"10.1016\/j.taap.2023.116475_bb0180","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1124\/jpet.103.050716","article-title":"The site-specific transport and metabolism of tacrolimus in rat small intestine","volume":"306","author":"Tamura","year":"2003","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.taap.2023.116475_bb0185","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1517\/17425255.2016.1170808","article-title":"Pharmacogenetic aspects of the use of tacrolimus in renal transplantation: recent developments and ethnic considerations","volume":"12","author":"Tang","year":"2016","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.taap.2023.116475_bb0190","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1097\/01.TP.0000137789.58694.B4","article-title":"Influence of CYP3A5 and MDR1 (ABCB1) polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients","volume":"78","author":"Tsuchiya","year":"2004","journal-title":"Transplantation"},{"key":"10.1016\/j.taap.2023.116475_bb0195","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/bcpt.13492","article-title":"BCPT policy for experimental and clinical studies","volume":"128","author":"Tveden-Nyborg","year":"2021","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"10.1016\/j.taap.2023.116475_bb0200","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1097\/FTD.0b013e31828c1581","article-title":"Genetic polymorphisms in ABCB1 influence the pharmacodynamics of tacrolimus","volume":"35","author":"Vafadari","year":"2013","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.taap.2023.116475_bb0205","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1111\/ajt.14232","article-title":"Determinants of the magnitude of interaction between tacrolimus and Voriconazole\/Posaconazole in solid organ recipients","volume":"17","author":"Vanhove","year":"2017","journal-title":"Am. J. Transplant."},{"key":"10.1016\/j.taap.2023.116475_bb0210","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1124\/dmd.118.081935","article-title":"Relationship between in vivo CYP3A4 activity, CYP3A5 genotype, and systemic tacrolimus metabolite\/parent drug ratio in renal transplant recipients and healthy volunteers","volume":"46","author":"Vanhove","year":"2018","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.taap.2023.116475_bb0215","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1038\/clpt.2014.43","article-title":"PBPK model describes the effects of comedication and genetic polymorphism on systemic exposure of drugs that undergo multiple clearance pathways","volume":"95","author":"Vieira","year":"2014","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.taap.2023.116475_bb0220","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1002\/psp4.12511","article-title":"Data digitizing: accurate and precise data extraction for quantitative systems pharmacology and physiologically-based pharmacokinetic modeling","volume":"9","author":"Wojtyniak","year":"2020","journal-title":"CPT Pharmacometrics Syst. Pharmacol."},{"key":"10.1016\/j.taap.2023.116475_bb0225","first-page":"669","article-title":"Research Progress on influencing factors of tacrolimus concentration in patients undergoing organ transplant","volume":"41","author":"Wu","year":"2022","journal-title":"Herald of Med."},{"key":"10.1016\/j.taap.2023.116475_bb0230","doi-asserted-by":"crossref","first-page":"513","DOI":"10.2174\/1389200219666180129151948","article-title":"Pharmacokinetics, pharmacodynamics and pharmacogenetics of tacrolimus in kidney transplantation","volume":"19","author":"Yu","year":"2018","journal-title":"Curr. Drug Metab."},{"key":"10.1016\/j.taap.2023.116475_bb0235","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/bcpt.12914","article-title":"Prediction of drug-drug interaction between tacrolimus and principal ingredients of Wuzhi capsule in Chinese healthy volunteers using physiologically-based pharmacokinetic modelling","volume":"122","author":"Zhang","year":"2018","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"10.1016\/j.taap.2023.116475_bb0240","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1007\/s00228-012-1432-1","article-title":"Effect of the P450 oxidoreductase 28 polymorphism on the pharmacokinetics of tacrolimus in Chinese healthy male volunteers","volume":"69","author":"Zhang","year":"2013","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.taap.2023.116475_bb0245","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1038\/clpt.2012.175","article-title":"Measurement and compartmental modeling of the effect of CYP3A5 gene variation on systemic and intrarenal tacrolimus disposition","volume":"92","author":"Zheng","year":"2012","journal-title":"Clin. Pharmacol. Ther."},{"issue":"8","key":"10.1016\/j.taap.2023.116475_bb0250","doi-asserted-by":"crossref","first-page":"699","DOI":"10.3109\/00498254.2012.756992","article-title":"Effect of amlodipine on the pharmacokinetics of tacrolimus in rats","volume":"43","author":"Zhou","year":"2013","journal-title":"Xenobiotica"},{"issue":"2","key":"10.1016\/j.taap.2023.116475_bb0255","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/s40262-020-00941-8","article-title":"Evaluation of Voriconazole CYP2C19 phenotype-guided dose adjustments by physiologically based pharmacokinetic modeling","volume":"60","author":"Zubiaur","year":"2021","journal-title":"Clin. Pharmacokinet."}],"container-title":["Toxicology and Applied Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041008X23001138?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041008X23001138?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T21:01:36Z","timestamp":1758574896000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0041008X23001138"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":51,"alternative-id":["S0041008X23001138"],"URL":"https:\/\/doi.org\/10.1016\/j.taap.2023.116475","relation":{},"ISSN":["0041-008X"],"issn-type":[{"value":"0041-008X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Physiologically-based pharmacokinetic modeling-guided rational combination of tacrolimus and voriconazole in patients with different CYP3A5 and CYP2C19 alleles","name":"articletitle","label":"Article Title"},{"value":"Toxicology and Applied Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.taap.2023.116475","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"116475"}}